Forwarded from 머지노의 Stock-Pitch
닉스 - 한미 - 에스티아이 + 피케홀
알테 - 오스코텍 - 유한양행
엔켐 - 이수스페셜티케미칼 - 레이크머티
알테 - 오스코텍 - 유한양행
엔켐 - 이수스페셜티케미칼 - 레이크머티
Forwarded from 바이오스펙테이터
Alteogen Finally Reveals Partner as MSD, Strikes Additional $450M Deal for Keytruda SC
Alteogen announced on the 22nd that it signed a contract with Merck (MSD) of the United States for the human hyaluronidase-based platform subcutaneous administration (SC) modification technology ‘ALT-B4’. In addition to the existing contract, it is a deal worth a total of $452 million, including a down payment of $20 million and a milestone increase.
http://m.biospectator.com/view/news_view.php?varAtcId=21169
Alteogen announced on the 22nd that it signed a contract with Merck (MSD) of the United States for the human hyaluronidase-based platform subcutaneous administration (SC) modification technology ‘ALT-B4’. In addition to the existing contract, it is a deal worth a total of $452 million, including a down payment of $20 million and a milestone increase.
http://m.biospectator.com/view/news_view.php?varAtcId=21169
바이오스펙테이터
Alteogen Finally Reveals Partner as MSD, Strikes Additional $450M Deal for Keytruda SC
Alteogen announced on the 22nd that it signed a contract with Merck (MSD) of the United States for the human hyaluronidase-based platform su